BLAINTRAVENOUSINJECTABLE1 Generic Approved
Approved
Mar 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
TYENNE (tocilizumab-aazg) by Fresenius Kabi is interleukin 6 receptor antagonists [moa]. First approved in 2024.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TYENNE (tocilizumab-aazg) is a monoclonal antibody antagonist of the interleukin-6 receptor, approved as a biosimilar or follow-on biologic in March 2024. It is administered intravenously and is indicated for conditions driven by IL-6 pathway dysregulation. The drug works by blocking IL-6 receptor signaling, reducing inflammatory cytokine activity.
Growth
Early-stage growth profile suggests expanding commercial team and field presence as market penetration accelerates post-launch.
Mechanism of Action
Interleukin 6 Receptor Antagonists
Pharmacologic Class:
Interleukin-6 Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TYENNE offers career opportunity in a growth-stage biologic launch with developing market presence and competitive positioning. Roles span commercial strategy, payor engagement, and field execution, with strong demand for market access expertise given biosimilar-specific reimbursement complexity.
Brand Manager
Worked on TYENNE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.